Comparison of Salicylic Acid 30% Peel and Pneumatic Broadband Light in the Treatment of Mild to Moderately Severe Facial Acne Vulgaris

Rattapon Thuangtong, MD; Chinmanat Tangjaturonrusamee, MD; Pinyo Rattanaumpawan, MD, PhD; Chérie M. Ditre, MD

Acne patients experience not only a medical disease but also an aesthetic condition, and this latter complication greatly motivates patients to seek out the best treatment regimen to hasten improvement in their appearance. The available clinical procedures for acne treatment include salicylic acid 30% peel and pneumatic broadband light (PBBL). The objective of this study was to compare the efficacy of salicylic acid 30% peel and PBBL treatments in patients with mild to moderately severe facial acne vulgaris. Twelve patients were recruited for a 12-week prospective, single-blind, randomized, split-face study. Patients were treated with a salicylic acid 30% peel on one side of the face and PBBL treatment was administered on the opposite side of the face for 6 consecutive weeks without other acne treatments. At every visit, treatment evaluations were performed using a modified Global Acne Grading Score (mGAGS), acne quality of life (QOL) questionnaire, Wong-Baker FACES Pain Rating Scale (WBPRS) assessments, and clinical photography. Improvement in acne symptoms was observed for both treatment procedures without significant differences and with minimal side effects. Salicylic acid 30% peel and PBBL were well tolerated in our study, and both clinical procedures were efficacious and well-tolerated by the patients.

Facial acne vulgaris is a common skin disease among teenagers and adolescents that may negatively affect self-esteem, perceived facial attractiveness, and social participation.1 Treatments for acne often are multimodal and require the utmost adherence. For these reasons, acne treatments have been challenging to clinicians and patients alike, as patient compliance in maintaining the use of prescribed topical and oral medications remains essential to attain improvement in quality of life (QOL). Salicylic acid is a popular medicament for acne treatment that frequently is used as monotherapy or as an adjuvant for other acne treatments, especially in patients with oily skin.2 Salicylic acid has a keratolytic effect, causing corneocyte dishesion in clogged pores or congested follicles,2 and it is effective in treating both inflammatory and noninflammatory acne.3,4

Light therapy, particularly with visible light, has been demonstrated to improve acne outcomes.5 Pneumatic broadband light (PBBL) is a therapeutic light treatment in the broadband range (400–1200 nm) that is combined with vacuum suction, which creates a mechanical lysis of thin-walled pustules and dislodges pore impaction. Additionally, the blue light portion of the PBBL spectrum targets endogenous porphyrins in Propionibacterium acnes, resulting in bacterial destruction.6-8

The purpose of this study was to compare the efficacy, tolerability, and safety of salicylic acid 30% peel versus PBBL in the treatment of mild to moderately severe facial acne vulgaris.


PRACTICE POINTS

- Salicylic acid peel and pneumatic broadband light (PBBL) are good alternative options in treating acne in addition to regular oral and topical treatments.
- Both salicylic acid peel and PBBL are effective, safe, and tolerable.

Drs. Thuangtong and Rattanaumpawan are from the Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Dr. Thuangtong is from the Department of Dermatology, and Dr. Rattanaumpawan is from the Department of Medicine. Dr. Tangjaturonrusamee is from the Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok. Dr. Ditre is from the Department of Dermatology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, and Penn Medicine Radnor, Pennsylvania.

The authors report no conflict of interest.

Correspondence: Chérie M. Ditre, MD, Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, 250 King of Prussia Rd, Radnor, PA 19087 (cherie.ditre@uphs.upenn.edu).
METHODS

Study Design
This single-blind, randomized, split-face pilot study was approved by the institutional review board of the University of Pennsylvania (Philadelphia, Pennsylvania). All patients provided informed consent before entering the study. The single-blind evaluation was performed by one dermatologist (C.T.) who examined the participants on every visit prior to PBBL treatment.

Before the study started, participants were randomized for which side of the face was to be treated with PBBL using a number assigned to each participant. Participants received both treatments—salicylic acid 30% peel on one side of the face and PBBL treatment on the other side of the face—once weekly for a total of 6 treatments. They were then asked to return for 2 follow-up evaluations at weeks 3 and 6 following the last treatment session and were instructed not to use any topical or oral acne medications during these follow-up periods.

Inclusion and Exclusion Criteria
Patients aged 18 years and older of any race and sex with noninflammatory papules, some inflammatory papules, and no more than 1 nodule (considered as mild to moderately severe facial acne) were included in the study. Participants had not been on any topical acne medications for at least 1 month and/or oral retinoids for at least 1 year prior to the study period. All women completed urine pregnancy tests prior to the study and were advised to utilize birth control during the study period.

Study Treatments
Salicylic Acid 30% Peel—The participant’s face was cleansed thoroughly before application of salicylic acid 30% (1.5 g/2.5 mL) to half of the face and left on for 5 minutes by the lesion type and number of lesions factors: local score = factor rated by clinical assessment × factor rated by number of lesions. The local score is the sum of the individual local scores (Table 1).

Efficacy Evaluation
A comparison of the efficacy of the treatments was determined by clinical evaluation and examining the results of the outcome measurements with the modified Global Acne Grading Score (mGAGS) and Acne QOL Scale during each treatment visit. Facial photographs were taken at each visit.

Modified Global Acne Grading Score—The mGAGS is a modification of the Global Acne Grading Scale (GAGS) that has been used to evaluate acne severity in many studies. It includes 6 locations on the face with a grading factor for each location. The local score is obtained by multiplying the factor rated by location with the factor of clinical assessment: local score = factor rated by location × factor rated by clinical assessment. The total score is the sum of the individual local scores (Table 1).

Although the original GAGS incorporates the type and location of the lesions in its calculation, we felt that the number of lesions also was important to add to our grading score. Therefore, we modified the GAGS by adding a factor rated by the number of lesions to improve the accuracy of the test. Accordingly, the local mGAGS scores were calculated by multiplying the location factor by the lesion type and number of lesions factors: local score = location factor × lesion type factor × number of lesions factor.

Pneumatic Broadband Light—On the other side of the face, PBBL was performed to deliver broadband light within the spectrum range of 400 to 1200 nm at a setting approximately equivalent to a fluence of 4 to 6 J/cm² and a vacuum setting approximately equivalent to a negative pressure of 3 lb/in². The power setting was increased on each subsequent visit depending on each participant’s tolerability.

Participants were required to apply a moisturizer and sunscreen to the face and avoid excessive sun exposure between study visits.

### TABLE 1. Acne Grading Scores

<table>
<thead>
<tr>
<th>Proposed Acne Grading Score</th>
<th>Factor Rated by Location</th>
<th>Factor Rated by Clinical Assessment</th>
<th>Factor Rated by Numbers of Lesions</th>
<th>Local Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAGS</td>
<td>Forehead, 2; right cheek, 2; left cheek, 2; nose, 1; chin, 1; chest/upper back, 3</td>
<td>0=no lesion; 1=≥1 comedone; 2=≥1 papule; 3=≥1 pustule; 4=≥1 nodule</td>
<td>N/A</td>
<td>Local score = L × A; the sum of local scores = global score*a</td>
</tr>
<tr>
<td>mGAGS</td>
<td>Forehead, 2; right cheek, 2; left cheek, 2; nose, 1; chin, 1; chest/upper back, 3</td>
<td>0=no lesion; 1=≥1 comedone; 2=≥1 papule; 3=≥1 pustule; 4=≥1 nodule</td>
<td>1=0–10 lesions; 2=11–20 lesions; 3=21–30 lesions; 4=≥31 lesions</td>
<td>Local score = L × A × N; the sum of local scores = modified global score*b</td>
</tr>
</tbody>
</table>

Abbreviations: GAGS, Global Acne Grading Scale; N/A, not available; L, factor rated by location; A, factor rated by clinical assessment; mGAGS, modified Global Acne Grading Score; N, factor rated by number of lesions.

*aThe global score determines the severity of acne: 0=none; 1–18=mild; 19–38=moderate; 31–38=severe; >39=very severe.

*bThe modified global score determines the severity of acne: 0=none; 1–44=mild; 45–80=moderate; 81–132=severe; 133–176=very severe.
Acne QOL Questionnaire—Acne QOL was assessed during each visit to demonstrate if the treatment results affected participants’ socialization due to appearance. Participants were asked to complete the questionnaire, which consisted of 9 questions with 4 rating answers (0=not affected; 1=mildly affected; 2=moderately affected; 3=markedly affected). A total score of 9 or higher (high score) indicated that acne had a substantial negative impact on the participant, while a total score below 9 (low score) meant acne scarcely impacted social aspects and daily activities of the patient.

Safety Evaluation
The safety of the treatments was evaluated by clinical inspection and by comparing the results of the Wong-Baker FACES Pain Rating Scale (WBPRS) after treatment. The WBPRS is used worldwide among researchers to assess pain, particularly in children. It is composed of 6 faces expressing pain with word descriptions with a corresponding number range reflecting pain severity from 0 to 5 (0=no hurt; 1=hurts little bit; 2=hurts little more; 3=hurts even more; 4=hurts whole lot; 5=hurts worst).

Statistical Analysis
All variables were presented as the median (range). A Wilcoxon signed rank test was used to compare clinical responses between the salicylic acid 30% peel and PBBL therapies. SPSS software version 12.0 was used for all statistical analysis. A 2-tailed $P$ value of ≤.05 was considered statistically significant.

RESULTS
Study Population
Twelve participants (2 males, 10 females) aged 17 to 36 years (median age, 22 years; mean age [SD], 23.33 [1.65] years) with both comedonal and inflammatory acne were enrolled into this study for 6 split-face treatments of salicylic acid 30% peel and PBBL at 1-week intervals for 6 weeks, with 2 subsequent follow-up sessions at weeks 3 and 6 posttreatment. Of the 12 participants, 11 were white and 1 was Asian American, with Fitzpatrick skin types II to IV. Nine participants (75%) completed the study. One participant dropped out of the study after the fourth treatment due to a scheduling conflict, and the other 2 participants did not return for follow-up. No participants withdrew from the study because of adverse therapeutic events.

Efficacy Evaluation
Comparisons between the salicylic acid 30% peel and PBBL procedures for mGAGS at each visit are shown in Table 2. There was no significant difference in treatment efficacy between the salicylic acid 30% peel and PBBL therapies during the study’s treatment and follow-up events; however, both procedures contributed to a major improvement in acne symptoms by the third treatment session and through to the last follow-up session ($P$.05). Clinical photographs at baseline, at last treatment visit (week 6), and at last follow-up (week 12) are shown in Figures 1 and 2.

The results of the acne QOL questionnaire are shown in Table 2. Lower scores reflect a higher QOL. Median QOL scores at each visit ranged from 0.5 to 4.5. There was no significant difference found between the peel agent or PBBL based on the baseline QOL and subsequent visit assessments; however, the differences between the 2 treatments were significant at weeks 3 ($P=.05$) and 5 ($P=.03$) of treatment as well as at the last follow-up visit ($P=.05$).

According to the QOL scores, by the third treatment session participants were more satisfied with their improved acne condition from the PBBL procedure than the salicylic acid 30% peel as demonstrated by a positive range of the QOL assessments between PBBL and salicylic acid 30% peel (as shown in the difference in QOL in Table 2: week 3, 0–6; week 4, 0–3; week 5, 0–7). On the other hand, participants saw more improvement from the salicylic acid 30% peel than from PBBL by the last follow-up.
### TABLE 2. Median mGAGS and QOL Scores

<table>
<thead>
<tr>
<th></th>
<th>Salicylic Acid 30% Peel</th>
<th>PBBL</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Median (Range)</td>
<td>P Value</td>
</tr>
<tr>
<td><strong>mGAGS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>12</td>
<td>15 (4–31)</td>
<td>N/A</td>
</tr>
<tr>
<td>1 wk</td>
<td>12</td>
<td>14 (4–31)</td>
<td>.16</td>
</tr>
<tr>
<td>2 wk</td>
<td>12</td>
<td>12.5 (8–21)</td>
<td>.11</td>
</tr>
<tr>
<td>3 wk</td>
<td>12</td>
<td>12 (2–17)</td>
<td>.02a</td>
</tr>
<tr>
<td>4 wk</td>
<td>11</td>
<td>10 (6–21)</td>
<td>.02a</td>
</tr>
<tr>
<td>5 wk</td>
<td>10</td>
<td>12 (4–30)</td>
<td>.24</td>
</tr>
<tr>
<td>6 wk</td>
<td>10</td>
<td>10 (4–34)</td>
<td>.04a</td>
</tr>
<tr>
<td>9 wk (FU1)</td>
<td>10</td>
<td>9.5 (4–22)</td>
<td>.02a</td>
</tr>
<tr>
<td>12 wk (FU2)</td>
<td>9</td>
<td>9 (4–16)</td>
<td>.01a</td>
</tr>
<tr>
<td><strong>QOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>12</td>
<td>4.5 (0–13)</td>
<td>N/A</td>
</tr>
<tr>
<td>1 wk</td>
<td>12</td>
<td>4.5 (0–13)</td>
<td>.32</td>
</tr>
<tr>
<td>2 wk</td>
<td>12</td>
<td>1.5 (0–13)</td>
<td>.11</td>
</tr>
<tr>
<td>3 wk</td>
<td>12</td>
<td>1.5 (0–11)</td>
<td>.05a</td>
</tr>
<tr>
<td>4 wk</td>
<td>11</td>
<td>2 (0–13)</td>
<td>.12</td>
</tr>
<tr>
<td>5 wk</td>
<td>10</td>
<td>2 (0–12)</td>
<td>.11</td>
</tr>
<tr>
<td>6 wk</td>
<td>10</td>
<td>2 (0–9)</td>
<td>.12</td>
</tr>
<tr>
<td>9 wk (FU1)</td>
<td>10</td>
<td>2 (0–14)</td>
<td>.14</td>
</tr>
<tr>
<td>12 wk (FU2)</td>
<td>9</td>
<td>3 (0–11)</td>
<td>.35</td>
</tr>
</tbody>
</table>

Abbreviations: mGAGS, modified Global Acne Grading Score; QOL, quality of life; PBBL, pneumatic broadband light; N/A, not available; FU, follow-up.

*aStatistically significant.*

**FIGURE 2.** A 19-year-old woman with mild acne who was treated with pneumatic broadband light on the left side of the face at baseline (A), week 6 (B), and week 12 (C).
evaluation, as the differences in QOL scores between the 2 treatments resulted in a negative range (−5–0).

Safety
Pain assessment by the WBPRS at every visit showed a low pain rating associated with both salicylic acid 30% peel (range, 0–0.5) and PBBL (range, 1.0–1.5) treatments. The median pain score of the salicylic acid 30% peel appeared higher compared to the PBBL treatment, yet a significant difference between both treatments was seen only at weeks 1, 3, and 6 of treatment (P≤.05).

There were no unexpected therapeutic reactions reported in our study, and no participants withdrew from the study due to adverse events. Most participants experienced only mild adverse reactions, including redness, stinging, and a burning sensation on the salicylic acid 30% peel side, which were transient and disappeared in minutes; only redness occurred on the PBBL-treated side.

Comment
Facial acne treatment is challenging, as prolonged and/or severe acne contributes to scarring, declining self-confidence, and undesirable financial consequences. Even though salicylic acid peel is a commonly used acne treatment choice, the PBBL methodology was approved by the US Food and Drug Administration and has become an alternative procedure for acne treatment.

The pharmacological effects of salicylic acid are related to its corneocyte desquamation and exfoliative actions, thereby reducing corneocyte cohesion and unclogging follicular pores. Salicylic acid has been demonstrated to ameliorate inflammatory acne by its effects on the arachidonic acid cascade. In our study, salicylic acid 30% peel met participants’ satisfaction in acne improvement similar to a study showing a 50% improvement in acne scores after just 2 treatments. Our data support and corroborate that salicylic acid 30% peel renders an improvement in acne sequelae reported in several other studies.

Pneumatic broadband light has been known to treat acne by the mechanism of pneumatic suction combined with photodynamic therapy using broadband-pulsed light (400–1200 nm). By applying the pneumatic device, a vacuum is created on the skin to remove sebum contents from follicles, whereas broadband light is emitted simultaneously to destroy bacteria and decrease the inflammatory process. During the vacuum process, the skin is stretched to reduce pain and avoid competitive chromophores (eg, hemoglobin), while the broadband light is administered. Broadband light encompasses 2 main light spectrums: blue light (415 nm) activates coproporphyrin III, which induces reactive free radicals and singlet oxygen species and has been reported to be the cause of bacterial cell death, and red light (633 nm), which renders an increase of fibroblast growth factors to work against the inflammatory processes. There are numerous studies showing a reduction of acne lesions after photopneumatic therapy with minimal side effects.

In our study, we compared the efficacy of salicylic acid 30% peel with PBBL in the treatment of acne. Both treatments showed significant reduction of mGAGS compared to baseline starting from week 3 and lasting until week 12. Remarkably, although there were some participants who reported acne recurrence after completing all treatments at week 6, which could have happened when the treatments were ended, the final acne score at week 12 was still significantly lower than baseline. It is clear that the participants continued their acne improvement up to the 6-week follow-up period without any topical or oral medication. We do not propose that either salicylic acid peel or PBBL treatment is a solitary option but speculate that the combination of both treatments may initiate a faster resolution in the disappearance of acne.

Although there was no statistically significant difference in efficacy between salicylic acid 30% peel and PBBL procedures at each visit, QOL assessments related to treatment satisfaction did yield significant differences between baseline and the end of treatment. We noticed that participants had more positive attitudes toward the PBBL side at week 3 and week 5 but only mild satisfaction at week 4, as the differences in QOL scores between both treatments showed positive ranging values. This finding is most likely related to the immediate reduction of acne pusules by the PBBL vacuum lysis of these lesions. The differences in the QOL scores between both treatments at week 12 (the last follow-up evaluation) provided opposite findings, which meant patients had nearly even improvement in both PBBL method and salicylic acid 30% peel.

Therefore, according to QOL data, acne disappeared quickly with the application of PBBL therapy but reappeared on the PBBL-treated side by the follow-up evaluations, though the acne score between both sides showed no statistically significant difference.

We reason that the PBBL therapy works better than salicylic acid 30% peel because the pneumatic system may help to unclog the pores through mechanical debridement via suctioning versus desquamation from salicylic acid 30% peel. Nonetheless, salicylic acid 30% peel sustained improvement when compared to PBBL through the follow-up periods. Both salicylic acid 30% peel and PBBL treatments are well tolerated and may initiate a faster resolution in the improvement of acne when incorporated with a medical program.

Because of the recurrence of acne after treatments were stopped, additional medical therapies are advised to be used along with this study’s clinical treatments to help mitigate the acne symptoms. These treatments should be considered in patients concerned about antibiotic resistance or those who cannot take oral antibiotics or retinoids. Salicylic acid peel is more accessible and affordable than PBBL, whereas PBBL is slightly more tolerable and less irritating than salicylic acid peel. Nevertheless, the cost of investment in PBBL is quite high—as much as $70,000—and does not
include disposable, single-use tips, which cost $30 each. The machine is easy to set up, weighs about 40 lb, and requires little space to store. The average cost per visit of PBBL treatment in office is $150.00 and $75.00 for salicylic acid peel (unpublished data, Hospital of the University of Pennsylvania, 2010). Most patients may select salicylic acid peel over PBBL due to the cost and convenience of the treatment. Neither procedure should be considered as a solitary treatment option but rather as adjunctive procedures combined with oral and/or topical acne medications. After this study’s treatments were stopped and without other medications to maintain treatment effectiveness, the lesions reappeared, trending back toward baseline.

**Conclusion**
Both salicylic acid 30% peel and PBBL procedures are effective, safe, and well tolerated in treating acne. Although there was no significant difference in the efficacy between both treatments in this study, the small sample size and short follow-up intervals warrant further studies to support the observed outstanding outcomes and should be considered in combination with other medical treatment options. These procedures may be beneficial in holding the patient compliant until their medical therapies have an opportunity to work.

**Acknowledgment**—The authors would like to thank Joyce Okawa, RN (Philadelphia, Pennsylvania), for her assistance in the submission to the institutional review board of the University of Pennsylvania.

**REFERENCES**